Morgan Stanley has initiated coverage on Mankind Pharma with an Overweight rating and a target price of Rs 2,500, implying 23% upside. The brokerage expects steady revenue growth and strong EPS expansion, supported by domestic recovery and BSV integration, while recent share price weakness reflects near-term pressures in acute therapies.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets